1. AlvarJ, VelezID, BernC, HerreroM, DesjeuxP, et al. (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671.
2. OsorioEY, ZhaoW, EspitiaC, SaldarriagaO, HawelL, et al. (2012) Progressive visceral leishmaniasis is driven by dominant parasite-induced STAT6 activation and STAT6-dependent host arginase 1 expression. PLoS Pathog 8: e1002417.
3. GreenSJ, NacyCA, MeltzerMS (1991) Cytokine-induced synthesis of nitrogen oxides in macrophages: a protective host response to Leishmania and other intracellular pathogens. J Leukoc Biol 50: 93–103.
4. LiewFY, LiY, MossD, ParkinsonC, RogersMV, et al. (1991) Resistance to Leishmania major infection correlates with the induction of nitric oxide synthase in murine macrophages. Eur J Immunol 21: 3009–3014.
5. GordonS, MartinezFO (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32: 593–604.
6. MartinezFO, HelmingL, GordonS (2009) Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 27: 451–483.
7. KenneyRT, SacksDL, GamAA, MurrayHW, SundarS (1998) Splenic cytokine responses in Indian kala-azar before and after treatment. J Infect Dis 177: 815–818.
8. KarpCL, el-SafiSH, WynnTA, SattiMM, KordofaniAM, et al. (1993) In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma [see comments]. J Clin Invest 91: 1644–1648.
9. GidwaniK, JonesS, KumarR, BoelaertM, SundarS (2011) Interferon-gamma release assay (modified QuantiFERON) as a potential marker of infection for Leishmania donovani, a proof of concept study. PLoS Negl Trop Dis 5: e1042.
10. SinghOP, GidwaniK, KumarR, NylenS, JonesSL, et al. (2012) Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. Clin Vaccine Immunol 19: 961–966.
11. HailuA, van BaarleD, KnolGJ, BerheN, MiedemaF, et al. (2005) T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. Clin Immunol 117: 182–191.
12. NylenS, MauryaR, EidsmoL, ManandharKD, SundarS, et al. (2007) Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 204: 805–817.
13. SundarS, ReedSG, SharmaS, MehrotraA, MurrayHW (1997) Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg 56: 522–525.
14. ZwingenbergerK, HarmsG, PedrosaC, OmenaS, SandkampB, et al. (1990) Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferon-gamma production. Clin Immunol Immunopathol 57: 242–249.
15. GautamS, KumarR, MauryaR, NylenS, AnsariN, et al. (2011) IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis 204: 1134–1137.
16. OlivierM, GregoryDJ, ForgetG (2005) Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view. Clin Microbiol Rev 18: 293–305.
17. MelbyPC, ChandrasekarB, ZhaoW, CoeJE (2001) The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like response. J Immunol 166: 1912–1920.
18. PerezLE, ChandrasekarB, SaldarriagaOA, ZhaoW, ArteagaLT, et al. (2006) Reduced nitric oxide synthase 2 (NOS2) promoter activity in the Syrian hamster renders the animal functionally deficient in NOS2 activity and unable to control an intracellular pathogen. J Immunol 176: 5519–5528.
19. IniestaV, Gomez-NietoLC, CorralizaI (2001) The inhibition of arginase by N(omega)-hydroxy-l-arginine controls the growth of Leishmania inside macrophages. J Exp Med 193: 777–784.
20. StempinCC, DulgerianLR, GarridoVV, CerbanFM (2010) Arginase in parasitic infections: macrophage activation, immunosuppression, and intracellular signals. J Biomed Biotechnol 2010: 683485.
21. IniestaV, Carlos Gomez-NietoL, MolanoI, MohedanoA, CarcelenJ, et al. (2002) Arginase I induction in macrophages, triggered by Th2-type cytokines, supports the growth of intracellular Leishmania parasites. Parasite Immunol 24: 113–118.
22. IniestaV, CarcelenJ, MolanoI, PeixotoPM, RedondoE, et al. (2005) Arginase I induction during Leishmania major infection mediates the development of disease. Infect Immun 73: 6085–6090.
23. KropfP, FuentesJM, FahnrichE, ArpaL, HerathS, et al. (2005) Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo. Faseb J 19: 1000–1002.
24. StempinC, GiordanengoL, GeaS, CerbanF (2002) Alternative activation and increase of Trypanosoma cruzi survival in murine macrophages stimulated by cruzipain, a parasite antigen. J Leukoc Biol 72: 727–734.
25. BabuS, KumaraswamiV, NutmanTB (2009) Alternatively activated and immunoregulatory monocytes in human filarial infections. J Infect Dis 199: 1827–1837.
26. BenoitM, BarbaratB, BernardA, OliveD, MegeJL (2008) Coxiella burnetii, the agent of Q fever, stimulates an atypical M2 activation program in human macrophages. Eur J Immunol 38: 1065–1070.
27. El KasmiKC, QuallsJE, PesceJT, SmithAM, ThompsonRW, et al. (2008) Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat Immunol 9: 1399–1406.
28. RaesG, Van den BerghR, De BaetselierP, GhassabehGH, ScottonC, et al. (2005) Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J Immunol 174: 6561 author reply 6561–6562.
29. RodriguezPC, OchoaAC (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 222: 180–191.
30. RodriguezNE, ChangHK, WilsonME (2004) Novel program of macrophage gene expression induced by phagocytosis of Leishmania chagasi. Infect Immun 72: 2111–2122.
31. MattilaJT, OjoOO, Kepka-LenhartD, MarinoS, KimJH, et al. (2013) Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol 191: 773–784.
32. PessanhaAP, MartinsRA, Mattos-GuaraldiAL, ViannaA, MoreiraLO (2012) Arginase-1 expression in granulomas of tuberculosis patients. FEMS Immunol Med Microbiol 66: 265–268.
33. OchoaJB, BernardAC, O'BrienWE, GriffenMM, MaleyME, et al. (2001) Arginase I expression and activity in human mononuclear cells after injury. Ann Surg 233: 393–399.
34. AbebeT, HailuA, WoldeyesM, MekonenW, BilchaK, et al. (2012) Local increase of arginase activity in lesions of patients with cutaneous leishmaniasis in ethiopia. PLoS Negl Trop Dis 6: e1684.
35. AbebeT, TakeleY, WeldegebrealT, ClokeT, ClossE, et al. (2013) Arginase activity - a marker of disease status in patients with visceral leishmaniasis in ethiopia. PLoS Negl Trop Dis 7: e2134.
36. MullerAK, MeyerM, WernerS (2012) The roles of receptor tyrosine kinases and their ligands in the wound repair process. Semin Cell Dev Biol 23: 963–970.
37. PortaC, LarghiP, RimoldiM, TotaroMG, AllavenaP, et al. (2009) Cellular and molecular pathways linking inflammation and cancer. Immunobiology 214: 761–777.
38. OsorioY, TraviBL, RensloAR, PenicheAG, MelbyPC (2011) Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system. PLoS Negl Trop Dis 5: e962.
39. ZongCS, ChanJ, LevyDE, HorvathC, SadowskiHB, et al. (2000) Mechanism of STAT3 activation by insulin-like growth factor I receptor. J Biol Chem 275: 15099–15105.
40. JiangH, HarrisMB, RothmanP (2000) IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol 105: 1063–1070.
41. LuH, HuangD, SaederupN, CharoIF, RansohoffRM, et al. (2011) Macrophages recruited via CCR2 produce insulin-like growth factor-1 to repair acute skeletal muscle injury. FASEB J 25: 358–369.
42. WernerS, GroseR (2003) Regulation of wound healing by growth factors and cytokines. Physiol Rev 83: 835–870.
43. YunYR, WonJE, JeonE, LeeS, KangW, et al. (2010) Fibroblast growth factors: biology, function, and application for tissue regeneration. J Tissue Eng 2010: 218142.
44. ModolellM, ChoiBS, RyanRO, HancockM, TitusRG, et al. (2009) Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis. PLoS Negl Trop Dis 3: e480.
45. NoelW, RaesG, Hassanzadeh GhassabehG, De BaetselierP, BeschinA (2004) Alternatively activated macrophages during parasite infections. Trends Parasitol 20: 126–133.
46. PuzikA, RuppJ, TrogerB, GopelW, HertingE, et al. (2012) Insulin-like growth factor-I regulates the neonatal immune response in infection and maturation by suppression of IFN-gamma. Cytokine 60: 369–376.
47. Jimenez-SousaMA, AlmansaR, de la FuenteC, Caro-PatonA, RuizL, et al. (2010) Increased Th1, Th17 and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin. Eur Cytokine Netw 21: 84–91.
48. MlamboNC, HylanderB, BraunerA (1999) Increased levels of transforming growth factor beta 1 and basic fibroblast growth factor in patients on CAPD: a study during non-infected steady state and peritonitis. Inflammation 23: 131–139.
49. SkevakiCL, PsarrasS, VolonakiE, PratsinisH, SpyridakiIS, et al. (2012) Rhinovirus-induced basic fibroblast growth factor release mediates airway remodeling features. Clin Transl Allergy 2: 14.
50. TourdotS, MathieS, HussellT, EdwardsL, WangH, et al. (2008) Respiratory syncytial virus infection provokes airway remodelling in allergen-exposed mice in absence of prior allergen sensitization. Clin Exp Allergy 38: 1016–1024.
51. EngwerdaCR, AtoM, CotterellSE, MynottTL, TschannerlA, et al. (2002) A role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection. Am J Pathol 161: 429–437.
52. YurdakulP, DaltonJ, BeattieL, BrownN, ErguvenS, et al. (2011) Compartment-specific remodeling of splenic micro-architecture during experimental visceral leishmaniasis. Am J Pathol 179: 23–29.
53. KayePM, SvenssonM, AtoM, MaroofA, PolleyR, et al. (2004) The immunopathology of experimental visceral leishmaniasis. Immunol Rev 201: 239–253.
54. VeressB, OmerA, SatirAA, El HassanAM (1977) Morphology of the spleen and lymph nodes in fatal visceral leishmaniasis. Immunology 33: 605–610.
55. WoodruffAW, TopleyE, KnightR, DownieCG (1972) The anaemia of kala-azar. Br J Haematol 22: 319–329.
56. ReisLC, Ramos-SanchezEM, GotoH (2013) The interactions and essential effects of intrinsic insulin-like growth factor-I on Leishmania (Leishmania) major growth within macrophages. Parasite Immunol 35: 239–244.
57. VendrameCM, CarvalhoMD, RiosFJ, ManuliER, Petitto-AssisF, et al. (2007) Effect of insulin-like growth factor-I on Leishmania amazonensis promastigote arginase activation and reciprocal inhibition of NOS2 pathway in macrophage in vitro. Scand J Immunol 66: 287–296.
58. YoshinouchiM, MiuraM, GaozzaE, LiSW, BasergaR (1993) Basic fibroblast growth factor stimulates DNA synthesis in cells overexpressing the insulin-like growth factor-I receptor. Mol Endocrinol 7: 1161–1168.
59. KardamiE, PearsonTW, BeecroftRP, FandrichRR (1992) Identification of basic fibroblast growth factor-like proteins in African trypanosomes and Leishmania. Mol Biochem Parasitol 51: 171–181.
60. BaxterRC (2000) Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab 278: E967–976.
61. BiswasA, BhattacharyaA, KarS, DasPK (2011) Expression of IL-10-triggered STAT3-dependent IL-4Ralpha is required for induction of arginase 1 in visceral leishmaniasis. Eur J Immunol 41: 992–1003.
62. WynesMW, RichesDW (2003) Induction of macrophage insulin-like growth factor-I expression by the Th2 cytokines IL-4 and IL-13. J Immunol 171: 3550–3559.
63. ChenF, LiuZ, WuW, RozoC, BowdridgeS, et al. (2012) An essential role for TH2-type responses in limiting acute tissue damage during experimental helminth infection. Nat Med 18: 260–266.
64. MyersMGJr, GrammerTC, WangLM, SunXJ, PierceJH, et al. (1994) Insulin receptor substrate-1 mediates phosphatidylinositol 3′-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. J Biol Chem 269: 28783–28789.
65. HellerNM, QiX, JunttilaIS, ShireyKA, VogelSN, et al. (2008) Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages. Sci Signal 1: ra17.
66. KimJH, ParkHH, LeeCE (2003) IGF-1 potentiation of IL-4-induced CD23/Fc(epsilon)RII expression in human B cells. Mol Cells 15: 307–312.
67. PatelBK, WangLM, LeeCC, TaylorWG, PierceJH, et al. (1996) Stat6 and Jak1 are common elements in platelet-derived growth factor and interleukin-4 signal transduction pathways in NIH 3T3 fibroblasts. J Biol Chem 271: 22175–22182.
68. ZuluagaS, Alvarez-BarrientosA, Gutierrez-UzquizaA, BenitoM, NebredaAR, et al. (2007) Negative regulation of Akt activity by p38alpha MAP kinase in cardiomyocytes involves membrane localization of PP2A through interaction with caveolin-1. Cell Signal 19: 62–74.
69. CheekatlaSS, AggarwalA, NaikS (2012) mTOR signaling pathway regulates the IL-12/IL-10 axis in Leishmania donovani infection. Med Microbiol Immunol 201: 37–46.
70. RuhlandA, KimaPE (2009) Activation of PI3K/Akt signaling has a dominant negative effect on IL-12 production by macrophages infected with Leishmania amazonensis promastigotes. Exp Parasitol 122: 28–36.
71. RuhlandA, LealN, KimaPE (2007) Leishmania promastigotes activate PI3K/Akt signalling to confer host cell resistance to apoptosis. Cell Microbiol 9: 84–96.
72. NandanD, Camargo de OliveiraC, MoeenrezakhanlouA, LopezM, SilvermanJM, et al. (2012) Myeloid cell IL-10 production in response to leishmania involves inactivation of glycogen synthase kinase-3beta downstream of phosphatidylinositol-3 kinase. J Immunol 188: 367–378.
73. ChavesJ, SaifMW (2011) IGF system in cancer: from bench to clinic. Anticancer Drugs 22: 206–212.
74. DanieleG, CorralJ, MolifeLR, de BonoJS (2012) FGF receptor inhibitors: role in cancer therapy. Curr Oncol Rep 14: 111–119.
75. DaltonJE, MaroofA, OwensBM, NarangP, JohnsonK, et al. (2010) Inhibition of receptor tyrosine kinases restores immunocompetence and improves immune-dependent chemotherapy against experimental leishmaniasis in mice. J Clin Invest 120: 1204–1216.
76. NylenS, SacksD (2007) Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 28: 378–384.
77. WilsonME, JeronimoSM, PearsonRD (2005) Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog 38: 147–160.
78. SacksDL, MelbyPC (2001) Animal models for the analysis of immune responses to leishmaniasis. Curr Protoc Immunol Chapter 19: Unit 19 12.
79. van der MeideW, GuerraJ, SchooneG, FarenhorstM, CoelhoL, et al. (2008) Comparison between quantitative nucleic acid sequence-based amplification, real-time reverse transcriptase PCR, and real-time PCR for quantification of Leishmania parasites. J Clin Microbiol 46: 73–78.